Literature DB >> 15371627

HIV-1 induces cardiomyopathyby cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling.

Milan Fiala1, Waldemar Popik, Jian-Hua Qiao, Albert S Lossinsky, Timothy Alce, Kenix Tran, Wendy Yang, Kenneth P Roos, James Arthos.   

Abstract

We examined heart tissues of AIDS patients with or without HIV cardiomyopathy (HIVCM) by immunohistochemistry, in situ polymerase chain reaction, in situ riboprobe hybridization, and the TUNEL technique for apoptosis. In HIVCM tissues, only inflammatory cells, but not endothelial cells or cardiomyocytes, displayed HIV-1 DNA and RNA. However, macrophages, lymphocytes, and--in a patchy fashion--cardiomyocytes and endothelial cells exhibited virus envelope protein gp120. Macrophages infiltrated the myocardium in a perivascular fashion and expressed tumor necrosis factor family ligands; adjacent cardiomyocytes suffered apoptosis. In vitro HIV-1 strongly invaded neonatal rat ventricular myocytes (NRVMs) and coronary artery endothelial cells (CAECs) and induced microvilli but did not replicate. HIV-1, gp120, or Tat induced Erk 1/2 phosphorylation, activation of caspase-3, and apoptosis of NRVMs and CAECs; all of these were inhibited by a MAPK/ERK-kinase (MEK) inhibitor U0126. The pathogenesis of HIVCM involves HIV-1 replication in inflammatory cells and induction of cardiomyocyte apoptosis by (1) the extrinsic pathway through apoptotic ligands and (2) the intrinsic pathway through direct virus entry and gp120- and Tat-proapoptotic signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371627     DOI: 10.1385/ct:4:2:097

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  28 in total

1.  Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.

Authors:  Raza M Alvi; Maryam Afshar; Anne M Neilan; Noor Tariq; Malek Hassan; Jaime Gerber; Magid Awadalla; Connor P Mulligan; Adam Rokicki; Virginia A Triant; Markella V Zanni; Tomas G Neilan
Journal:  Am Heart J       Date:  2019-01-11       Impact factor: 4.749

2.  The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1.

Authors:  Kunjal Patel; Russell B Van Dyke; Murray A Mittleman; Steven D Colan; James M Oleske; George R Seage
Journal:  AIDS       Date:  2012-10-23       Impact factor: 4.177

3.  Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Melissa Skanderson; Olga V Patterson; Scott L DuVall; Cynthia A Brandt; Kaku A So-Armah; Ramachandran S Vasan; Kris Ann Oursler; John Gottdiener; Stephen Gottlieb; David Leaf; Maria Rodriguez-Barradas; Russell P Tracy; Cynthia L Gibert; David Rimland; Roger J Bedimo; Sheldon T Brown; Matthew Bidwell Goetz; Alberta Warner; Kristina Crothers; Hilary A Tindle; Charles Alcorn; Justin M Bachmann; Amy C Justice; Adeel A Butt
Journal:  JAMA Cardiol       Date:  2017-05-01       Impact factor: 14.676

Review 4.  Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries.

Authors:  Gerald S Bloomfield; Fawaz Alenezi; Felix A Barasa; Rebecca Lumsden; Bongani M Mayosi; Eric J Velazquez
Journal:  JACC Heart Fail       Date:  2015-08       Impact factor: 12.035

5.  Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins.

Authors:  Antonella Bugatti; Chiara Urbinati; Cosetta Ravelli; Erik De Clercq; Sandra Liekens; Marco Rusnati
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

Review 6.  Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat.

Authors:  Ting Wang; Ru Yi; Linden Ann Green; Sarvesh Chelvanambi; Michael Seimetz; Matthias Clauss
Journal:  Cardiovasc Pathol       Date:  2015-07-09       Impact factor: 2.185

7.  Mitochondrial dysfunction in human immunodeficiency virus-1 transgenic mouse cardiac myocytes.

Authors:  Joseph Y Cheung; Jennifer Gordon; JuFang Wang; Jianliang Song; Xue-Qian Zhang; Fabian Jana Prado; Santhanam Shanmughapriya; Sudarsan Rajan; Dhanendra Tomar; Farzaneh G Tahrir; Manish K Gupta; Tijana Knezevic; Nana Merabova; Christopher D Kontos; Joseph M McClung; Paul E Klotman; Muniswamy Madesh; Kamel Khalili; Arthur M Feldman
Journal:  J Cell Physiol       Date:  2018-09-07       Impact factor: 6.384

8.  Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathy.

Authors:  James J Kohler; Seyed H Hosseini; William Lewis
Journal:  Chem Res Toxicol       Date:  2008-04-05       Impact factor: 3.739

9.  Relationships among HIV infection, metabolic risk factors, and left ventricular structure and function.

Authors:  William Todd Cade; Edgar Turner Overton; Kristin Mondy; Lisa de las Fuentes; Victor G Davila-Roman; Alan D Waggoner; Dominic N Reeds; Sherry Lassa-Claxton; Melissa J Krauss; Linda R Peterson; Kevin E Yarasheski
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-06       Impact factor: 2.205

10.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.